Stelara shows favorable safety profile through 1-year of IBD treatment

Data from six phase 2/3 studies showed that Stelara had a favorable safety profile through 1-year of treatment in Crohn’s disease and ulcerative colitis, according to research published in Inflammatory Bowel Diseases.William J. Sandborn, MD, of the University of California, San Diego, and colleagues wrote that previous research — including in psoriatic disease — has demonstrated a good safety profile for the drug (ustekinumab, Janssen), but integrated analysis of combined patients with IBD, could help physicians make treatment choices.“This increases the precision toRead More

Share on facebook
Share on twitter
Share on linkedin